Browse Category

NYSE:TEX News 30 October 2025

Terex (TEX) Stock Crashes 18% on Surprise REV Group Merger News

Terex (TEX) Stock Crashes 18% on Surprise REV Group Merger News

In-Depth Analysis Terex’s stock slump on Oct. 30 came amid two shocks: mixed Q3 earnings results and a transformational merger announcement. After a previous close near $56, shares briefly traded in the mid-$40s, reflecting roughly an 18% intraday fallstockanalysis.comts2.tech. Ts2.tech noted that “Terex fell ~18%” after the quarter (“weaker revenue”) newsts2.tech, a move echoed by institutional traders and option activity. By afternoon, volume had spiked and the stock was well below pre-earnings levels. For context, the 52-week range is $31.53–$58.66stockanalysis.com, so even after the drop, shares remain above their 2025 low (around $32 last winter) but well off recent highs.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop